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Abstract: The endothelium can evoke relaxations (dilatations) of the underlying vascular 
smooth muscle, by releasing vasodilator substances. The best characterized endothelium-
derived relaxing factor (EDRF) is nitric oxide (NO). The endothelial cells also evoke 
hyperpolarization of the cell membrane of vascular smooth muscle (endothelium-
dependent hyperpolarizations, EDHF-mediated responses). Endothelium-dependent 
relaxations involve both pertussis toxin-sensitive Gi (e.g. responses to serotonin, and 
thrombin) and pertussis toxin-insensitive Gq (e.g. adenosine diphosphate and bradykinin) 
coupling proteins. The release of NO by the endothelial cell can be up- (e.g. by estrogens, 
exercise and dietary factors) and down-regulated (e.g. oxidative stress, smoking and 
oxidized low-density lipoproteins [oxyLDL]). It is reduced in the course of vascular 
disease (e.g. diabetes and hypertension). Arteries covered with regenerated endothelium 
(e.g. following angioplasty) selectively loose the pertussis-toxin sensitive pathway for NO-
release which favors vasospasm, thrombosis, penetration of macrophages, cellular growth 
and the inflammatory reaction leading to atherosclerosis. In addition to the release of NO 
(and causing endothelium-dependent hyperpolarizations), endothelial cells also can evoke 
contraction (constriction) of the underlying vascular smooth muscle cells by releasing 
endothelium-derived contracting factor (EDCF). Most endothelium-dependent acute 
increases in contractile force are due to the formation of vasoconstrictor prostanoids 
(endoperoxides and prostacyclin) which activate TP-receptors of the vascular smooth 
muscle cells. EDCF-mediated responses are exacerbated when the production of nitric 
oxide is impaired (e.g. by oxidative stress, aging, spontaneous hypertension and diabetes).  
They contribute to the blunting of endothelium-dependent vasodilatations in aged subjects 
and essential hypertensive patients.  
 
Short Title : NO, EDCF and Endothelial Dysfunction 





The seminal observation of Robert Furchgott demonstrated that the removal of the endothelial 
layer from isolated arteries prevents the in vitro dilator response to acetylcholine [Furchgott & 
Zawadzki, 1980]. This simple experiment has profoundly modified our thinking about the local 
control of vasomotor tone. Early bioassay studies demonstrated that the endothelial cells cause 
arterial relaxation by releasing a powerful vasoactive substance(s) which was termed 
endothelium-derived relaxing factor (EDRF) (Figure 1) [Furchgott & Zawadzki, 1980; Rubanyi 
et al., 1985]. The original EDRF [Furchgott & Zawadzki, 1980] stimulates soluble guanylyl 
cyclase in the vascular smooth muscle cells and thus increases the production of cyclic guanosine 
monophosphate (cyclic GMP) [see Ignarro et al., 1986; Furchgott & Vanhoutte, 1989; Lüscher & 
Vanhoutte 1990]. It is rapidly destroyed by superoxide anions [Rubanyi et al., 1986; Gryglewski 
et al., 1986]. These experimental facts led to the proposal [Furchgott, 1988; Ignarro et al., 1988a, 
1988b] and the demonstration [Palmer et al., 1987, 1988, 1989; Moncada, 1997] that EDRF is 
nitric oxide (NO) (Figure 2).   However, the release of NO is by no means the only way to evoke 
endothelium-dependent vasomotor changes. Thus, besides NO, a number of endothelium-derived 
factors (EDHFs) and the opening of gap junctions can cause NO-independent hyperpolarizations 
of the   underlying vascular smooth muscle (Figure 3) [see Busse et al., 2002; Feletou & 
Vanhoutte 2006a, 2006b, 2007]. In addition, endothelial cells can release vasoconstrictor 
prostanoids (endothelium-derived contracting factors, EDCF) (Figure 4) [see Furchgott & 
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Vanhoutte, 1989; Lüscher & Vanhoutte, 1990, Vanhoutte, 1993a; Vanhoutte et al., 2005]. When 
the ability of the endothelial cells to release NO [and to cause endothelium-dependent 
hyperpolarizations] is reduced, and in particular if the propensity to produce EDCF is enhanced, 
endothelial dysfunction ensues, which appears to be the first step in the chain of events that leads 
to atherosclerosis and coronary disease [see Vanhoutte, 1988, 1996, 1997, 2002, 2003; 
Vanhoutte & Shimokawa, 1989; Shepherd & Vanhoutte, 1991; Urakami-Harasawa et al., 1997; 
Feletou & Vanhoutte, 2006c].  Thus, endothelial dysfunction has become a hallmark, and indeed 
a predictor of cardiovascular disease [e.g. Lyons, 1997; Behrendt & Ganz, 2002; Li et al., 2002b; 
Ganz & Vita 2003; Dickson & Gotlieb, 2004; Frstermann and Münzel, 2006; Landmesser & 
Drexler 2007, Ross et al., 2008]. This brief, non-exhaustive review focuses on the imbalance 
between opposing endothelium-derived mediators, in particular NO and EDCFs, and its role in 
the genesis of vascular disease.  
 
2. Nitric Oxide: 
2.1 Protector of the vascular wall  
As such, the endothelium-dependent relaxation to acetylcholine is more of pharmacological than 
of physiological interest. Indeed few peripheral blood vessels are innervated by cholinergic 
nerves, the most likely source of acetylcholine. When present, the cholinergic neurons are 
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located in the adventitia, making the access to the endothelial cells rather unlikely. A number of 
more physiological stimuli [physical forces, circulating hormones (catecholamines, vasopressin, 
aldosterone), platelet products (serotonin, adenosine diphosphate), autacoids (histamine, 
bradykinin), prostaglandin E4, thrombin] share with acetylcholine the ability to elicit 
endothelium-dependent changes in the tone of the underlying smooth muscle(Figure 1) [see 
Vanhoutte et al., 1986; Lüscher & Vanhoutte, 1990; Pearson & Vanhoutte 1993; Stähli et al., 
2006; Hristovska et al., 2007; Levine et al., 2007; Touyz, 2007; Tang et al., 2008]. NO plays a 
key role in the protection exerted by the endothelium against coronary disease. It is produced by 
the Ca2+-dependent constitutive isoform of NO synthase (eNOS, NOS III) (Figure 2) [Marletta, 
1989; Schini-Kerth & Vanhoutte, 1995; Moncada, 1997; Li et al., 2002a; Dudzinski et al., 2006; 
Feron and Balligand, 2006; O’Rourke et al., 2006]. NO not only prevents abnormal constriction 
(vasospasm) of the coronary arteries, which favors intraluminal clot formation, but also inhibits 
the aggregation of platelets, the expression of adhesion molecules at the surface of the 
endothelial cells, and hence the adhesion and penetration of white blood cells (macrophages), 
and the release and action of the vasoconstrictor and mitogenic peptide endothelin-1 (Figure 5). 
The protective release of NO is triggered by the local presence of thrombin and substances 
released by aggregating platelets.  When this protective role of NO is curtailed, the inflammatory 
response [Ross 1999] that leads to atherosclerosis is initiated [Vanhoutte, 1988, 1996, 1997, 
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2000, 2002; Feletou & Vanhoutte, 2006; Lüscher et al., 1993; Li et al., 2002b; Vallance, 2003; 
Cooke, 2004; Voetsch et al., 2004].  
The role played by the endothelial cells to protect against thrombin and platelet products by 
increasing the activity of eNOS has been demonstrated both in vitro [De Mey et al., 1982; Cohen 
et al., 1983, 1984; Houston et al., 1985, 1986; Shimokawa et al., 1988; Derkach et al., 2000; 
Motley et al., 2007, Touyz, 2007] and in vivo [Shimokawa & Vanhoutte, 1991].  Serotonin (5-
hydroxytryptamine, 5HT) and adenosine diphosphate (ADP) are the two mediators released by 
aggregating platelets that can activate eNOS and thus augment the production of NO. Serotonin 
is the most important and stimulates 5-HT1D serotonergic receptors of the endothelial cell 
membrane. ADP is a relatively minor contributor that acts on P2y purinoceptors (Figure 5). The 
serotonergic receptors and those for thrombin are coupled to the activation of eNOS through 
pertussis toxin-sensitive Gi-proteins, while the P2y-purinoceptors are linked to the enzyme by 
Gq- proteins [Flavahan et al., 1989; Shimokawa et al., 1991; Flavahan & Vanhoutte, 1995].If the 
endothelium is absent or dysfunctional such relaxations are no longer observed, and aggregating 
platelets induce constrictions (vasospasm), because they release the powerful vasoconstrictors 
thromboxane A2 and serotonin.  
The physiological importance of the endothelium-dependent relaxations to platelet products is 
obvious [see Vanhoutte, 1988, 1996, 1997, 2002; Feletou & Vanhoutte, 2006b]. Thus, if platelet 
aggregation occurs in a coronary artery with a healthy endothelium the release by the platelets of 
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serotonin (and ADP) and the local production of thrombin will stimulate the endothelial cells 
with the resulting release of NO. The endothelial mediator will cause the underlying smooth 
muscle to relax, thus increasing blood flow and mechanically impeding the progression of the 
coagulation process. NO also exerts in synergy with prostacyclin an immediate feed-back 
inhibition on the platelets [Radomski et al., 1987]. When the endothelial barrier is interrupted by 
injury, the aggregating platelets can approach the vascular smooth muscle cells, and cause their 
contraction by releasing thromboxane A2   and serotonin, initiating the vascular phase of 
hemostasis. The endothelium-dependent response to aggregating platelets is not present to the 
same extent in all arteries, but is the most prominent in the coronary and cerebral circulations.  
2.2. Modulation of the protective role of Nitric Oxide 
The ability of the endothelium to release NO can be up- or down-regulated in the intact organism 
by a number of chronic factors.  
2.2.1 Up-regulation 
Shear Stress: Both acute and chronic increases in flow, and the resulting increasing force of 
shearing (shear stress) of the blood on the endothelial cells, augment the expression and the 
activity (in a Ca2+-independent way) of eNOS, and thus the release of EDRF/NO (Figure 2) 
[Rubanyi et al., 1986; Miller & Vanhoutte, 1988; Davies, 1995; Davis et al., 2001; Stepp et al., 
2001; Busse & Fleming, 2003; Bellien et al., 2006; Spier et al., 2007; Yan et al., 2007]. This 
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immediate effect of an increase in shear stress on the release of NO explains flow-mediated 
dilatation (FMD), a phenomenon often used to estimate the functional state of the endothelium in 
humans.  In the coronary circulation, the effect of shear stress involves the local production of 
the autacoid bradykinin that stimulates the release of NO through a Gq-dependent mechanism 
(Figure 6) [Flavahan et al., 1989; Shimokawa et al., 1991; Mombouli & Vanhoutte, 1991, 1995; 
Roves et al., 1995]. The chronic effect of shear stress is due to an up-regulation of eNOS and a 
greater activation (phosphorylation) of the enzyme, leading to a larger release of NO for each 
given stimulation, explaining the beneficial effects of regular exercise on endothelial function 
[Miller & Vanhoutte, 1988; Mombouli et al., 1996; Watts et al., 2004; Hambrecht et al., 2003; 
Suvorava et al., 2004; Lauer et al., 2005; Gertz et al., 2006; Rakobowchuk et al., 2008].  
Estrogens and Gender: Although ovariectomy does not alter or even increase the mRNA 
expression and the presence of eNOS [Wassman et al., 2001; Okano et al., 2006], the 
reintroduction of physiological levels of estrogens in ovariectomized animals augments 
endothelium-dependent relaxations to muscarinic agonists [Gisclard et al., 1988; Wassman et al., 
2001; Santos et al., 2004; Scott et al., 2007] and accelerates endothelial healing after injury 
[Filipe et al., 2008]. The potentiating effect of estrogens on endothelium-dependent relaxations 
involves both genomic (Figure 2) and non-genomic effects [see Tostes et al., 2003; Keung et al., 
2005; Miller & Duckles, 2008]. It depends presumably both on a reduction in oxidative stress 
leading to an increased bioavailability of the endothelium-derived mediator and an increased 
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responsiveness of the vascular smooth muscle cells to vasodilator stimuli [Wassman et al., 2001; 
Han et al., 2007; Li et al., 2007; Scott et al., 2007]. In the intact organism, a reduced production 
of the endogenous inhibitor of eNOS, asymmetric dimethyl arginine (ADMA) may contribute 
[Monsalve et al., 2007]. Phytoestrogens and selective estrogen receptor modulators (SERMs) 
also potentiate endothelium-dependent relaxations/vasodilatations [Lee & Man, 2003; Sbarouni 
et al., 2003; Wong et al., 2006; Chan et al., 2007; Leung et al., 2007]. In coronary arteries, the 
potentiating effect of chronic treatment with estrogens is seen only with stimuli that activate Gi-
coupled receptors on the endothelial cells and is counteracted by the chronic administration of 
progesterone [Miller & Vanhoutte, 1991]. It is likely that this potentiating effect of estrogens on 
NO release, presumably resulting from lower oxidative stress, helps to explain why endothelium-
dependent relaxations are more pronounced in arteries from female than male animals [Kauser & 
Rubanyi, 1995; Kähönen et al., 1998; Dantas et al., 2004] and thus why women are protected 
against coronary disease, at least until the age of menopause. The opposing effects of estrogens 
and progesterone could explain why hormone replacement therapy has not always had the 
expected beneficial effect on the occurrence of cardiovascular events.  
Insulin: Insulin facilitates NO-dependent vasodilatations in vivo [Steinberg et al., 1994; Taddei et 
al., 1995b; Lembo et al., 1997]. It enhances the expression of eNOS in native endothelial cells in 
vitro [Fisslthaler et al., 2003]. 
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Adiponectin: Adiponectin improves endothelial function and protects the endothelium by 
promoting eNOS activity and the bioavailability of NO [Chen et al., 2003; Hattori et al., 2003; 
Tan et al., 2004;Li et al., 2007b; Wang & Scherer, 2008; Zhu et al., 2008]. 
Other Hormones: In post-menopausal women, testosterone appears to potentiate endothelium-
dependent vasodilatation [Montalcini et al., 2007]. Thyroid hormone up-regulates eNOS and 
augments the endothelial production of NO in the animal [Spooner et al., 2004]. Adrenalectomy 
augments the expression of eNOS [Li et al. 2007a] and aldosterone acutely augments NO-
dependent relaxations by a non-genomic action [Nietlispach et al., 2007; Uhrenholt et al., 2003, 
2004; Skott et al., 2006]. Glucagon-like peptide-1 (GLP-1) enhances the vasodilator response to 
acetylcholine [Basu et al., 2007]. 
Diet: The chronic intake of ω3-unsaturated fatty acids potentiates the endothelium-dependent 
relaxations of coronary arteries to aggregating platelets and other stimuli and have 
antiatherogenic properties[Shimokawa et al., 1987, 1988; Shimokawa & Vanhoutte, 1989a,; 
Shepherd & Vanhoutte, 1991; von Schacky & Harris, 2007; Sena et al., 2008; Sekikawa et al., 
2008]. The same holds true for the intake of flavonoids [Machha & Mustafa, 2005; Machha et al. 
2007, Xu et al., 2007] and other polyphenols, whether present in red wine (in particular 
resveratrol) [Stockley, 1998; Leikert et al., 2002; Wallerath et al., 2002; da Luz & Coimbra, 
2004; Dell’Agli et al., 2004; Soares de Moura et al., 2004; Coimbra et al., 2005; Boban et al., 
2006; Sarr et al. 2006; Das et al., 2007; Lefevre  et al., 2007; Aubin et al., 2008; Chan et al., 
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2008a, 2008b; Csiszar et al., 2008; Lopez-Sepulveda et al., 2008], in green tea [Kuriyama et al., 
2006; Alexopoulos et al., 2008], grape juice [Anselm et al., 2007], in pomegranate juice [Nigris 
et al., 2005, 2007a, 2007b] or in dark chocolate [Fischer et al., 2003; Engler et al., 2004;Grassi et 
al., 2005; Schroeter et al., 2006; Flemmer et al., 2007; Taubert et al., 2007].  
Arginine: Although the acute administration of L-arginine can favor endothelium-dependent 
responses in humans [e.g. Bode-Boger et al., 1996; Taddei et al., 1997b; Perticone et al., 2005], 
its chronic supplementation offers no therapeutic benefit in patients with vascular disease 
[Wilson et al., 2007], reinforcing the early suspicion [Schini & Vanhoutte, 1991a] that the semi-
essential amino acid is rarely a limiting factor for the endothelial production of NO. An 
exception may be when the endothelial arginases, which compete with eNOS for this substrate, 
are more active  (Figure 6) [Ming et al., 2004; Ryoo et al, 2006, 2008; Brandes, 2006; Holowatz 
& Kenney, 2007; Santhanam et al., 2007; Katusic, 2007; Romero et al., 2008; Vanhoutte 2008]. 
2.2.2. Down-regulation: 
 Oxygen-derived free radicals: Several enzymes in the endothelial cells can produce superoxide 
anions (Figure 7). They include NADPH oxidase, xanthine oxidase, cyclooxygenase and eNOS 
itself, when it is uncoupled by lack of substrate (L-arginine) or shortage of the essential co-factor 
tetrahydrobiopterin (BH4) [see Kojda & Harrison 1999; Stuehr et al., 2001; Fleming et al., 
2005]. Superoxide anions can be dismutated by superoxide dismutase (SOD) to hydrogen 
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peroxide (H2O2) which can act as an EDHF and contribute to endothelium-dependent relaxations 
(Figure 2) [Matoba et al., 2000; Morikawa et al., 2003; Shimokawa & Matoba, 2004; Takaki et 
al., 2008; see Feletou & Vanhoutte, 2006a, 2006c, 2007], or been broken down by catalase. 
However, superoxide anions also scavenge NO avidly with the resulting formation of 
peroxynitrite [Rubanyi & Vanhoutte 1986; Gryglewski et al., 1986; Auch-Schwelk et al., 1992; 
Cosentino et al., 1994; Tschudi et al., 1996a; De Lano et al., 2006; Kagota et al., 2007; 
Miyagawa et al., 2007; Macarthur et al., 2008].  This reduces considerably the bioavailability of 
NO [see Kojda & Harrison, 1999]. Hence, increases in oxidative stress have been consistently 
associated with reduced endothelium-dependent relaxations, and antioxidants shown to acutely 
improve such responses in vitro and in vivo both in animals [e.g. Aubin et al., 2006; Liu et al., 
2007] and humans [e.g. Kanani et al., 1999; Taddei et al., 2001; Holowatz & Kenney, 2007]. 
However, the therapeutic relevance of these findings is questionable as chronic treatment with 
antioxidants usually fails to improve endothelial function in people [e.g. Duffy et al., 2001; 
Pellegrini et al., 2004], with maybe the exception of the chronic administration of low doses of 
folic acid [Moat et al., 2006]. 
Hormones: Long term exposure to aldosterone has a detrimental effect on NO-dependent 
relaxations,  presumably by reducing the production of the essential cofactor for eNOS, 
tetrahydrobiopterin and increasing oxidative stress [Mitchell et al., 2004; Hashikabe et al., 2006; 
Nagata et al., 2006; Skott et al., 2006; Nietlispach et al., 2007; Sartorio et al., 2007]. Melatonin 
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also inhibits the endothelial formation of NO [Silva et al., 2007]. Castration of male animals 
augments the vasodilator response to acetylcholine [Ajayi et al., 2004]. 
Aging: Both in animals and in humans, increasing age reduces the ability of the endothelium to 
elicit endothelium-dependent vasodilatations in vitro and in vivo [see Vanhoutte, 2002; Moritoki 
et al., 1986; Koga et al., 1988; Charpie et al., 1994; Davidge et al., 1996; Hongo et al., 1988; 
Kung & Lüscher,  1995; Taddei et al., 1997b, 2001; Cernadas et al., 1998; Yasuro et al., 1999; 
Heymes et al., 2000; Csiszar et al., 2002, 2007; Subramian & MacLeod, 2003;; Spier et al., 2007; 
Bulckaen et al., 2008]. This is due to an increased activity of arginase, competing with eNOS for 
the common substrate arginine [Santhanam et al., 2007; Katusic, 2007], an augmented 
production of oxygen-derived free radicals reducing the bioavailability of NO [Tschudi et al., 
1996a; Taddei et al., 2001; Csiszar et al., 2002, 2007] a reduced expression/presence of eNOS 
[Challah et al., 1997; Chou et al., 1998; Csiszar et al., 2002], a reduced activity of the enzyme 
[Cernadas et al., 1998] and ultimately a lesser release of NO [Tschudi et al., 1996a]. In addition, 
the expression of soluble guanylyl cyclase in aging vascular smooth muscle is reduced [Klöss et 
al., 2000]. However, an important part of the endothelial dysfunction with aging is due to the 
endothelial release of vasoconstrictor prostaglandins (see 3.2). 
Smoking and Environment: Active and passive smoking blunt endothelium-dependent 
vasodilatations. This appears to be due to an action of nicotine causing a greater formation of 
ADMA and to an increased production of oxygen-derived free radicals, both resulting in a lesser 
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availability of NO [de Sousa et al., 2005; Michaud et al., 2006; Gamboa et al., 2007; Celermajer 
& Ng, 2008; Argacha et al., 2008; Csiszar et al., 2008; Heiss et al., 2008; Lang et al., 2008]. 
Chronic exposure to air pollution decreases endothelium-dependent vasodilatations [Briet et al., 
2007].  
Homocysteinemia: Increased levels of homocysteine impair eNOS dependent 
relaxations/vasodilatations both in vitro and in vivo, presumably by increasing  oxidative stress 
[e.g. Bellamy et al., 1998; Chambers et al., 1999; Kanani et al., 1999; Lang et al., 2000; Hanratty 
et al., 2001; Liu et al., 2007; Looft-Wilson et al., 2008]. 
Hypercholesterolemia: Both in animals and in humans, hypercholesterolemia reduces 
endothelium-dependent relaxations/dilatations and the normalization of the cholesterol level with 
treatment restores the response [Shimokawa & Vanhoutte, 1989a, 1989b; Vanhoutte, 1991; 
Trochu et al., 2003; Kaul et al., 2004; Landmesser et al., 2005; August et al., 2006; Fichtlscherer 
et al., 2006; Inoue & Node, 2007; Aubin et al., 2008; Knight et al. 2008; Sena et al., 2008]. This 
is explained best by an increased oxidative stress leading to a reduced bioavailability of NO, an 
impairment of the turnover rate of eNOS and an increased presence of ADMA [Bode-Böger et 
al., 1996; Böger et al., 2001, 2004; August et al., 2006; Palm et al., 2007 ]. 
Obesity: Obese animals and humans exhibit reduced responses to endothelium-dependent 
vasodilators [Karagiannis et al., 2003; Van Guilder et al., 2006, 2008; Bouvet et al., 2007; 
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Kagota et al., 2007]. A major reason for the blunted endothelium-dependent relaxation is the 
production of EDCF (see 3). Weight loss alone or exercise training improve endothelium-
dependent responses [Watts et al., 2004; Focardi et al., 2007; Pierce et al., 2008; Ungvari et al., 
2008]. 
Sleep apnea: Intermittent hypoxia, as occurring with obstructive sleep apnea reduces 
endothelium-dependent responsiveness [Budhiraja et al., 2007]. 
 
2.3. Hallmark of disease 
Hypertension: Endothelium-dependent relaxations are reduced in isolated arteries from different 
animal models of hypertension [e.g. Lüscher et al., 1987a, 1987b; Hongo et al., 1988; Vanhoutte 
& Boulanger, 1995; Kung & Lüscher, 1995; Tschudi et al., 1996b; Vanhoutte, 1996; Shimokawa 
& Vanhoutte, 1997; Zhou et al., 1999]. Likewise, the response to endothelium-dependent 
vasodilators is blunted in hypertensive humans [e.g. Taddei et al., 1995a, 1997a, 2001; Perticone 
et al., 2005].  This blunting can be corrected by an appropriate treatment both in animals and in 
people [Lüscher et al.,  1987b; Hutri-Kahonen et al., 1997; Taddei et al., 1998; Benndorf et al., 
2007; Naya et al., 2007]. It probably reflects the premature aging of the vasculature exposed 
chronically to the increased arterial blood pressure [Taddei et al., 1997b]. In essential 
hypertension, the reduction in response to endothelium-dependent stimuli in vivo may be due in 
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part to higher circulating levels of ADMA [Perticone et al., 2005]. In the spontaneously 
hypertensive rats, the blunting of endothelium-dependent relaxations/vasodilatations is due 
mainly to the concomitant release of endothelium-derived vasoconstrictor prostanoids (see 3.3) 
rather than to a reduced release of NO [Lüscher & Vanhoutte 1986; Lüscher et al., 1987d; Koga 
et al., 1988; Yasuro et al., 1999] despite a lower expression of eNOS and soluble guanylyl 
cyclase in the arterial wall [Chou et al., 1998: Klöss et al., 2000; Michel et al., 2007] .  
Diabetes: Insulin resistance and diabetes cause an impairment of arterial endothelium-dependent 
relaxations in animals and humans, presumably due to the chronic exposure to hyperglycemia 
[see De Vriese et al., 2000; Vallerjo et al., 2000; Cheng et al., 2001; Paennirselvam et al., 2002; 
Guzik et al., 2002; Inkster et al., 2002; Nassar et al., 2002; Kim et al., 2003; Kim et al., 2006; Shi 
et al., 2006; Eringa et al., 2007; Goel et al., 2007; Machha et al., 2007; Obrosova et al., 2007; Shi 
et al., 2007a; Schäfer et al., 2008 ]. In the case of type 2 diabetes, a genetic predisposition to 
endothelial dysfunction may be involved [Iellamo et al., 2006]. The mechanisms underlying the 
reduced NO-dependent dilatations in diabetes include: a] reduced bioavailability of 
tetrahydrobiopterin and uncoupling of eNOS [Guzik et al., 2002; Pannirselvam et al., 2002; Alp 
et al., 2003; Cai et al., 2005]; b] increased activity of arginase competing with eNOS for the 
common substrate, arginine [Ming et al., 2004; Ryoo et al, 2006, 2008; Katusic, 2007; Lüscher 
& Steffel, 2008: Romero et al., 2008; Vanhoutte 2008]; c] elevated levels of the endogenous 
inhibitor of eNOSADMA [Lin et al., 2002; Xiong et al., 2003]; d] augmented production of 
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superoxide anions and thus scavenging of NO and increased presence of peroxynitrite [Cosentino 
et al., 1997; Mayhan & Patel, 1990; Graier et al., 1999; Maejima et al., 2001; Inkster et al., 2002; 
Pacher & Szabo, 2006; Duncan et al., 2007; Pannirselvam et al., 2002; Quijano et al., 2007; Gao 
et al., 2008; Lüscher & Steffel, 2008; Schäfer et al., 2008]; e] quenching of NO by advanced 
glycosylation products [Bucala et al., 1991; Yin & Xiong, 2005; Gao et al., 2008]; f] reduced 
presence of apelin [Zhong et al., 2007; Grisk, 2007]; and g] abnormal responsiveness of vascular 
smooth muscle [Lu et al., 2005; Lesniewski et al., 2008; Shi et al., 2008]. In addition to a 
reduced bioavailability of NO, the production of vasoconstrictor prostanoids contributes 
importantly to the endothelial dysfunction of diabetes (see 3.3). 
Coronary Disease: Individuals at increased risk of coronary heart disease are characterized by 
impaired peripheral dilatations in response to acetylcholine [Ijzerman et al., 2003]. Also in the 
coronary circulation, endothelial dysfunction is a characteristic of the disease. [e.g. Ludmer et 
al., 1986; Hodgson & Marshall, 1989; Vanhoutte et al., 1997; Shimokawa & Vanhoutte, 1997; 
Lavi et al., 2008]. Both in animals and humans, the presence of endothelial dysfunction predicts 
the severity of the outcome, in  particular the occurrence of myocardial infarction and stroke 
[Suwaidi et al., 2000; Halcox et al., 2002; Kuvin & Karas, 2003; Mancini, 2004; Ross et al., 
2008]. 
Heart Failure: Endothelium-dependent relaxations are reduced in coronary and peripheral 
arteries of animals and humans with ventricular hypertrophy and/or heart failure presumably 
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because of the increased oxidative stress resulting from under-perfusion of the tissues and the 
leading to down-regulation of eNOS and reduced bioavailability of NO [Kaiser et al., 1989; 
Treasure et al., 1990; Kubo et al., 1991; Katz et al., 1992; Zhao et al., 1995; Smith et al., 1996; 
Bauersachs et al., 1999; Indik et al., 2001; Nakamura et al., 2001; Landmesser et al., 2002; Malo 
et al., 2003; Trochu et al., 2003; Ferreiro et al., 2004; Widder et al., 2004; Lida et al., 2005; Gill 
et al., 2007; Ross et al., 2008]. An impairment of the ability of the vascular smooth muscle cells 
to relax contributes to the blunting of the endothelium-dependent responsiveness [Gill et al., 
2007]. The degree of impairment of endothelium-dependent vasodilatations predicts the outcome 
in patients with chronic heart failure [Meyer et al., 2005]. 
Pulmonary Hypertension: Chronic hypoxia resulting in pulmonary hypertension results in 
reduced endothelium-dependent relaxations of pulmonary arteries, because of an overproduction 
of oxygen-derived free radicals leading to reduced activity of eNOS, resulting from a tighter 
coupling to caveolin-1, and a diminished bioavailability of NO, a phenomenon exacerbated by 
the genetic deletion of bone morphogenetic protein receptors [Fresquet et al. 2006; Frank et al., 
2008]. In the monocrotaline-induced form of the disease, a similar endothelial dysfunction 
caused by oxygen-derived free radicals occurs in the right ventricle [Sun & Ku, 2006; Kajiya et 
al., 2007]. 
2.4. The weak link: regenerated endothelium 
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Endothelial cells form a monolayer mainly resulting from contact inhibition. After maturation of 
the body, they remain quiescent for many years before aging and apoptotic programming initiate 
their turnover. However, the latter is accelerated by cardiovascular risk factors such as 
hypertension and diabetes. Eventually, the apoptotic cells die and are removed by the blood 
stream. They are replaced rapidly by regenerated endothelial cells. It is still uncertain what the 
exact contribution in this regeneration process is of neighboring cells, freed of contact inhibition, 
and circulating endothelial progenitor cells [Vanhoutte, 1997; Hibbert et al.,2003; Sata, 2003; 
Dimmeler and Zeiher, 2004; Lamping, 2007; Filipe et al., 2008; Zampetaki et al., 2008].  
Regenerated endothelial cells are dysfunctional (Figure 8). This conclusion is based on 
experiments performed on porcine coronary arteries [Shimokawa et al., 1989d, 1991; Eto et al., 
2005]. Thus, one month after in vivo balloon denudation of the endothelium of part of the artery, 
despite total relining of the endothelial surface, rings covered with regenerated endothelium 
exhibited a marked blunting of the relaxations to aggregating platelets, serotonin or thrombin and 
the remaining response was no longer inhibited by pertussis toxin. By contrast, relaxations 
evoked by ADP and bradykinin, which both depend on the Gq-signaling cascade, as well as 
those to the calcium ionophore A23187  were normal, illustrating the ability of the regenerated 
endothelial cells to produce NO. These observations implied a selective dysfunction of the Gi-
dependent responses in regenerated endothelial cells. This selective dysfunction was reduced by 
the chronic intake of ω3-unsaturated fatty acid, and exacerbated by a chronic 
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hypercholesterolemic diet which resulted in the occurrence of typical atherosclerotic lesions in 
the area of previous denudation [Shimokawa & Vanhoutte, 1989a, 1989c]. These observations 
prompt the conclusion that the selective dysfunction of regenerated endothelial cells is the first 
step allowing the atherosclerotic process. 
To analyze the molecular mechanisms underlying the dysfunction of regenerated endothelial 
cells on primary cultures were derived from either regenerated or native endothelium [Borg-
Capra et al., 1997; Fournet-Bourguignon et al., 2000; Kennedy et al., 2003; Lee et al., 2007]. 
Primary cultures derived from regenerated endothelial cells had the appearance and markers of 
accelerated senescence, a reduced expression and activity of eNOS, a greater production of 
oxygen-derived free radicals (produced by the endothelial NADPH oxidase), took up more 
modified low-density lipoprotein cholesterol (LDL) and generated more oxidized LDL 
(oxyLDL). By contrast, the presence of Gi-proteins was comparable to that observed in primary 
cultures derived from the native endothelium. The genomic changes observed in cultures of 
regenerated endothelial cells were consistent with those phenotypic and functional changes.  
Increased extracellular concentrations of oxyLDL reduce the production of EDRF/NO and the 
endothelium-dependent relaxations to serotonin [Boulanger et al., 1985; Cox & Cohen, 1996]. 
Taken in conjunction, those observations prompt the conclusion assumption that an augmented 
presence of oxyLDL contributes to the selective loss in Gi-protein mediated responses of 
regenerated endothelial cells and thus of the inability to respond to serotonin and thrombin 
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[Figure 2]. Obviously, this is not the only negative effect of oxygen-derived free radicals and 
oxyLDL which play a central role in the atherosclerotic process  (Figure 9) [Stocker & Keany, 
2004, 2005; Li & Mehta, 2005; August et al., 2006]. Other factors include a direct inhibitory 
effect on the expression, reduced activation (dephosphorylation) and uncoupling of eNOS [Chu 
et al. 2005; Fleming et al., 2005; Brandes, 2006; Heeba et al., 2007] and an enhanced activity of 
arginase, which competes with NO for the common substrate arginine (Figure 6) [Ming et al., 
2004; Ryoo et al., 2006, 2008; Brandes, 2006; Katusic, 2007; Romero et al. 2008; Vanhoutte 
2008]. In addition, a greater production of superoxide anions will reduce the bioavailability of 
NO and increase the levels of peroxynitrite [Kojda & Harrison 1999; Vanhoutte, 2001; Fleming 
et al., 2005; Brandes, 2006; Heeba et al., 2007].  
Genomic factors and endogenous mediators, other than the increased presence of oxyLDL, may 
accelerate or contribute to the atherosclerotic process. These include: a]  emergence of fatty acid-
binding proteins [Lee et al., 2007; Furuhashi et al., 2007; Furuhashi & Hotamisligil, 2008; Hoo 
et al., 2008]; b] circulating  chemokines [Ardigo et al., 2007]; c] inhibition of the proteosome 
[Herrman et al., 2007]; d] presence of growth-related oncogene-α [Bechara et al., 2007]; and e] 
insufficiency of the Paraoxonase -1 gene [Guns et al., 2008]. 
Whatever the cause is of their dysfunction, the endothelial cells cannot produce enough NO in 
response to platelets and thrombin, and this NO deficiency permits the inflammatory reaction 
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3.1. The villains: endothelium-derived vasoconstrictor prostanoids 
As stated in the Introduction, the endothelium cells can also initiate contractions of the 
underlying vascular smooth muscle cells (Figure 3) [De Mey & Vanhoutte, 1982, 1983]. 
Bioassay studies demonstrated that diffusible substances are responsible for these endothelium-
dependent increases in vasomotor tone [Rubanyi & Vanhoutte, 1985; Iqbal & Vanhoutte, 1988; 
Yang et al., 2003]. Although endothelial cells can produce endothelin-1 [Yanagisawa et al., 
1988; Yanagisawa & Masaki, 1989; Schini & Vanhoutte, 1991b; Vanhoutte, 1993; Rubanyi & 
Polokoff, 1994; Böhm & Pernow, 2007; Kirkby et al., 2008] and other non-prostanoid 
vasoconstrictor substances [Dhein et al., 1997; Saifedine et al., 1998; Jankowski et al., 2005], the 
available evidence strongly suggests that that vasoconstrictor prostaglandins produced by 
cyclooxygenase in the endothelium explain most endothelium-dependent contractions (Figure 
10) [see Vanhoutte et al. 2005].  
EDCF-mediated responses: Endothelium-dependent, cyclooxygenase-dependent contractions to 
acetylcholine and other vasoactive substances [e.g. arachidonic acid, ATP, the calcium 
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ionophore A23187] have been observed in blood vessels from different species [Furchgott & 
Vanhoutte, 1989; Lüscher & Vanhoutte, 1990; Vanhoutte et al., 2005; Derkach et al., 2000; 
Kauser & Rubanyi, 1995; Kähönen et al., 1998; Davidge & Zhang, 1998; Wang et al., 2003].  
Key role of endothelial cyclooxygenase: Early studies already demonstrated that endothelium-
dependent contractions are prevented by non-selective inhibitors of cyclooxygenase [Miller & 
Vanhoutte, 1985; Lüscher & Vanhoutte, 1986; Katusic et al., 1988], exemplifying the pivotal 
role of this enzyme in the phenomenon [see Vanhoutte et al 2005]. Bioassay studies indicate that 
the vasoconstrictor prostanoids involved are produced by the endothelial cyclooxygenase, rather 
than that of the vascular smooth muscle (Figure 3) [Yang et al., 2003]. Studies in arteries of the 
spontaneously hypertensive rat (SHR) using preferential and selective inhibitors of the two 
isoforms of the enzyme (constitutive cyclooxygenase-1 [COX-1] and inducible cyclooxygenase-
2 [COX-2)], molecular biology experiments (Figure 4) and studies with blood vessels  of 
genetically modified mice concur to suggest that COX-1 is the major source of EDCF [Ge et al., 
1995; Traupe et al., 2002a ; Ospina et al., 2003; Wang et al., 2003; Yang et al., 2003; Tang et al., 
2005a; Gluais et al., 2006]. However, if endothelial COX-2 is induced, the prostanoids generated 
by this isoform also evoke endothelium-dependent contractions [Camacho et al., 1998; Zerrouk 
et al., 1998; Garcia-Cohen et al., 2000; Alvarez et al., 2005; Blanco-Rivero et al., 2005; Hirao et 
al., 2008; Shi & Vanhoutte, 2008]. 
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 Calcium, the trigger for release: Although the release of EDCF can be tonic [Iwatani et al., 
2008] or elicited by sudden stretch [Katusic et al., 1987], it usually is initiated by vasoactive 
mediators acting at the cell membrane, including acetylcholine (activating endothelial M3-
muscarinic receptors [Boulanger et al., 1994]) or ADP (activating purinoceptors [Koga et al., 
1989; Mombouli & Vanhoutte, 1993]). Endothelium-dependent contractions are less prominent 
in lower extracellular Ca2+-concentration, are reduced by Vitamin D derivatives, are triggered by 
calcium ionophores such as A23187, and are paralleled by an increase in endothelial cytosolic 
Ca2+-concentration [Katusic et al., 1988; Okon et al., 2002; Gluais et al., 2006; Shi et al., 2007a, 
2007b, 2008; Tang et al., 2007; Wong et al., 2008]. These findings prompt the conclusion that an 
increased intracellular Ca2+-concentration is the initial trigger for endothelium-dependent 
contractions, presumably by activating phospholipase A2 which then makes arachidonic acid 
available to the endothelial cyclooxygenase setting in motion the release of EDCF. 
When prostacyclin turns bad: Cyclooxygenase transforms arachidonic acid into endoperoxides 
which are released during endothelium-dependent contractions. Since endoperoxides per se can 
activate vascular smooth muscle they are an EDCF [Ito et al., 1991; Asano et al., 1994; Ge et 
al., 1995; Vanhoutte et al., 2005; Hirao et al., 2008]. Endoperoxides are converted into 
prostacyclin, thromboxane A2, prostaglandin D2, prostaglandin E2 and/or prostaglandin F2α by 
their selective synthases [Bos et al., 2004]. ). The expression of the prostacyclin synthase gene 
is the most abundant in endothelial cells. During endothelium-dependent contractions to 
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acetylcholine the release of prostacyclin outweighs that of other prostaglandins [Gluais et al., 
2005]. In arteries where endothelium-dependent contractions to the muscarinic agonist are 
prominent, prostacyclin does not evoke relaxation of the vascular smooth muscle [Rapoport & 
Williams, 1996; Gluais et al., 2005].Thus, it seems logical to conclude that endoperoxides and 
prostacyclin are the main mediators of these responses, at least for those evoked by 
acetylcholine [Ge et al., 1995; Blanco-Rivero et al., 2005; Gluais et al., 2005]. However, in 
particular during EDCF-mediated responses to other agonists (ADP, A23187, endothelin-1, 
thrombin, nicotine), thromboxane A2 contributes [Katusic et al., 1988;  Shirahase et al, 1988; 
Auch-Schwelk & Vanhoutte, 1992; Taddei & Vanhoutte, 1993; Derkach et al., 2000; Gluais et 
al., 2006, 2007].  
TP-receptors, the effector : Cyclooxygenase-dependent, endothelium-dependent contractions are 
inhibited by antagonists of thromboxane-prostanoid (TP) receptors [Tesfamariam et al., 1989; 
Auch-Schwelk et al., 1990; Kato et al., 1990; Mayhan, 1992; Yang et al., 2002, 2003; Zhou et al., 
2005]. The TP-receptors involved are those of the vascular smooth muscle which initiate the 
contractile response [Yang et al., 2003].  
 
3.2. Modulation of ECDF-mediated responses  
Reduction in NO production: Inhibitors of NO synthases cause an immediate potentiation of 
EDCF-mediated responses [Auch-Schwelk et al., 1992; Yang et al., 2002]. Previous exposure to 
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endogenous NO released from the endothelial cells or to exogenous NO-donors causes a long 
term inhibition of endothelium-dependent contractions [Tang et al., 2005b]. These observations 
imply that any condition resulting in a lesser bioavailability of NO will favor the occurrence of 
EDCF-mediated contractions/constrictions [Feletou et al., 2008]. 
Facilitation by oxygen-derived free radicals: In some arteries, SOD, that does not permeate 
cells, abolishes endothelium-dependent contractions suggesting that superoxide anions act as an 
intercellular messenger which turns on the production of vasoconstrictor prostanoids by the 
vascular smooth muscle cells [Katusic & Vanhoutte, 1989]). In other blood vessels, however, 
SOD does not affect endothelium-dependent contractions while cell-permeable scavengers of 
superoxide anions variably depress the response [Auch-Schwelk et al., 1989; Yang et al., 2002, 
2003; Tang & Vanhoutte, 2008a]. Acetylcholine and A23187 cause a burst of endothelial free 
radical production [Tang et al., 2007]. Since the burst, is prevented by indomethacin, 
cyclooxygenase appears to be the main source of superoxide anions, and their production is not 
a primary event [Tang et al, 2007]. The pharmacological data available indicate that, once 
produced, the free radicals amplify the EDCF-mediated response, presumably in part by 
stimulating cyclooxygenase of the endothelial cells but also possibly by activating that of the 
vascular smooth muscle [Auch-Schwelk et al., 1989; Garcia-Cohen et al., 2000; Wang et al., 
2003; Yang et al., 2002, 2003; Alvarez et al., 2008], although the latter conclusion is hard to 
reconcile with their extremely short half-life (with the exception of H2O2) . Thus it is unclear 
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how the  oxygen-derived free radicals may reach the vascular smooth muscle cells. Whether or 
not and how the myo-endothelial gap junctions play a role in this transition remains to be 
determined, despite the fact that gap junction inhibitors reduce EDCF-mediated responses [Tang 
& Vanhoutte, 2008a]. Obviously, the scavenging action of superoxide anions on NO, by 
reducing the bioavailability of the latter [Rubanyi & Vanhoutte 1986; Gryglewski et al., 1986; 
Auch-Schwelk et al., 1992; Cosentino et al., 1994; Tschudi et al., 1996b; Touyz & Schiffrin, 
2004; De Lano et al., 2006; Miyagawa et al., 2007; Macarthur et al., 2008] will also favor the 
occurrence of endothelium-dependent contractions. The resulting combination of the two 
radicals into peroxynitrite leads  to tyrosine nitration of prostacyclin synthase [Zou et al., 2002]. 
This may result in a compensatory production of prostaglandin E2 and prostaglandin F2α and 
thus in augmented endothelium-dependent contractions [Zou et al, 1999, Bachschmid et al, 
2003; Gluais et al., 2005]. 
Estrogens and Gender: In arteries of ovariectomized animals, chronic treatment with estrogens 
reduces the augmented production of vasoconstrictor prostanoids by endothelial COX-1 and 
reduces the augmented responsiveness of the TP-receptors on the vascular smooth muscle cells 
[Davidge & Zhang, 1998; Dantas et al., 1999; Ospina et al., 2003]. Estrogens also reduce acutely 
EDCF-mediated responses in an NO-independent way [Zhang & Kosaka, 2002]. The production 
of endothelium-derived prostanoids is larger in arteries from male than female animals [Kauser 
& Rubanyi 1995; Kähönen et al., 1998]. It is tempting to assume that the lesser occurrence of 
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cardiovascular disease in women prior to menopause is related in part to the braking effect of 
estrogens on EDCF-mediated responses. 
Aging: Endothelium-dependent contractions become more prominent with aging [Koga et al., 
1988, 1989; Iwama et al., 1992; Kung & Lüscher, 1995; Heymes et al., 2000; Abeywardena et 
al., 2002; Matsumoto et al. 2007]. Inhibitors of cyclooxygenase, given in vivo or in vitro, prevent 
or revert, respectively, the blunting of endothelium-dependent relaxations/vasodilatations due to 
aging [Koga et al., 1988, 1989; Davidge et al., 1996; Wang et al., 2003; Bulckaen et al., 2008]. 
TP-receptor antagonists have a similar effect [Kung & Lüscher, 1995; Davidge et al., 1996; 
Abeywardena et al., 2002]. The age-dependency of the response is explained best by an 
increased oxidative stress resulting in the up-regulation of COX-1 and/or the induction of COX-2 
[Ge et al;, 1995; Heymes et al., 2000; Matsumoto et al., 2007; Tang & Vanhoutte, 2008b; Shi et 
al., 2008]. In addition, the expression of the prostacyclin synthase gene augments with age 
[Numaguchi et al., 1999]. Prostacyclin no longer evokes relaxations in arteries from aging 
animals [Levy, 1980; Rapoport & Williams 1996; Gluais et al., 2005].  
Indomethacin  augments the relaxations to acetylcholine in isolated arteries of older patients  as 
well as the vasodilator response to the muscarinic agonist in the forearm of aging people, 
suggesting that the importance of EDCF-mediated responses also increases with age in the 
human [Lüscher et al., 1987c; Taddei et al., 1995a, 1997a, 1997b].  
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Obesity: High fat intake and obesity potentiate the occurrence of EDCF-mediated responses, 
possibly because of insulin resistance, resulting in greater production of oxygen-derived free 
radicals, an up-regulation of the expression of TP-receptors, and the unleashed production of 
endothelin-1 (Traupe et al., 2002a, b; Gollasch, 2002; Mundy et al., 2007; Xiang et al., 2008]. 
 
3.3. Hallmark of vascular disease: 
Hypertension: The endothelium-dependent relaxations to acetylcholine are blunted and the 
endothelium-dependent contractions to acetylcholine more pronounced in arteries of the SHR 
than in those of normotensive Wistar-Kyoto rats (WKY) (Figure 11) [Lockette et al., 
1986;Lüscher & Vanhoutte, 1986; Lüscher et al. 1987b; Lüscher & Vanhoutte, 1986; Koga et al., 
1989; Kähönen et al., 1998;]. These changes are prevented by inhibitors of cyclooxygenase and 
antagonists at TP-receptors [Lüscher & Vanhoutte, 1986; Kung & Lüscher, 1995; Zhou et al., 
1999; Koga et al., 1989; Yang et al., 2003] The increase in intracellular endothelial Ca2+-
concentration caused by acetylcholine is greater in SHR arteries than in those of the WKY, while 
during exposure to A23187 it is comparable, suggesting that a key aspect of the prominence of 
endothelium-dependent contractions in the former relates to an abnormal handling of calcium 
[Tang et al., 2007]. In addition, in the aorta of hypertensive strain the expression/presence of 
COX-1 is increased [Ge et al., 1995; Tang & Vanhoutte, 2008b]. However, this overexpression 
is not present in arteries of pre-hypertensive SHR [Ge et al., 1999; Tang & Vanhoutte, 2008b]. 
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These findings prompt the conclusion that the overexpression of the enzyme in arteries from 
adult hypertensive animals reflects premature aging of the endothelium rather than a genetic 
predisposition. The burst of endothelial free radicals is also greater in arteries of the SHR than in 
those of the WKY [Tang et al., 2007], implying a greater facilitation of EDCF-mediated 
responses. The expression of the prostacyclin synthase gene is more abundant in endothelial cells 
of the SHR than in the WKY endothelium, and the protein presence of the enzyme is augmented 
by hypertension [Numaguchi et al., 1999; Tang & Vanhoutte 2008b]. These endothelial changes 
explain why acetylcholine causes a greater release of endoperoxides and prostacyclin in SHR 
than in WKY arteries [Ge et al., 1995; Gluais et al., 2005]. Endothelium-dependent contractions 
are also facilitated by the fact that prostacyclin no longer causes relaxations in arteries of 
hypertensive animals [Rapoport & Williams, 1996; Gluais et al., 2005]. In addition, although the 
mRNA expression and protein presence of TP receptors are comparable in arteries of WKY and 
SHR [Tang & Vanhoutte, 2008b; Tang et al., 2008] the latter are hyper-responsive to the 
vasoconstrictor effect of endoperoxides and prostacyclin [Levy, 1980; Rapoport & Williams 
1996; Ge et al., 1995; Gluais et al., 2005]. This hyper-responsiveness is present in pre-
hypertensive animals [Ge et al., 1999]. Thus, it is not a consequence of premature aging following 
the chronic exposure to an increased arterial blood pressure, and it constitutes one of the genetic 
platforms of the disease. Obviously, the absence of vasodilator response to prostacyclin 
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contributes, and helps to explain why in humans cardiovascular disease is accelerated by a 
dysfunctional prostacyclin receptor mutation [Arehart et al., 2008] 
Aspirin and indomethacin potentiate the vasodilator response to acetylcholine in the forearm of 
patients with hypertension but not in that of normotensive subjects [Taddei et al., 1995a, 1997a, 
1997b; Monbe et al., 2001]. This then suggests that EDCF-mediated responses also are part of 
the endothelial dysfunction of human hypertension.  
Diabetes: The endothelium-dependent relaxations to acetylcholine are blunted in a number of 
arteries from diabetic animals [see Tesfamariam, 1994; De Vriese et al., 2000]. This is due in part 
to the concomitant release of EDCF and can be attributed to the exposure of the endothelial cells to 
high glucose, resulting in increased oxidative stress and overexpression of both COX-1 and COX-2 
[Tesfamariam et al., 1990, 1991; Xu et al., 2006; Michel et al., 2008b; Shi et al., 2006, 2007a, 
2007b, 2008; Obrosova et al., 2007; Shi & Vanhoutte, 2008]. In the case of diabetes, the 
production of ROS may play a more crucial role in triggering and amplifying EDCF-mediated 
responses [Shi et al., 2007b, 2008; Shi & Vanhoutte, 2008]. 
Coronary Disease: Aspirin and the TP-receptor inhibitor terutroban improve endothelial function 
in patients with coronary disease, suggesting that endothelium-derived prostanoids contribute to 





Native, healthy endothelial cells respond to a number of stimuli (e.g. serotonin from aggregating 
platelets and thrombin) by releasing NO, which relaxes the vascular smooth muscle that 
surrounds them. NO, in synergy with prostacyclin, further inhibits platelet aggregation. It also 
reduces the endothelial expression of adhesion molecules and thus the adhesion and penetration 
of leukocytes (macrophages). The endothelial mediator also prevents the proliferation of vascular 
smooth muscle cells and limits the formation of oxy LDL. Aging and certain lifestyle factors 
(e.g. lack of exercise, Western diet, pollution and smoking), or certain diseases (e.g. diabetes and 
hypertension) result in a lesser release of NO and an acceleration of the turnover of the apoptotic 
process in the endothelium. The apoptotic endothelial cells are replaced by regenerated ones. 
However, such regenerated cells are dysfunctional, senescent, and incapable of producing the 
required amounts of NO, which facilitates the inflammatory response leading to the formation of 
atherosclerotic plaques. The shortage of NO also unleashes the production of endothelium-
derived vasoconstrictor prostanoids (EDCF), in particular endoperoxides and prostacyclin. These 
prostanoids activate TP- receptors of the vascular smooth muscle leading to vasoconstriction 
which amplifies the degree of endothelial dysfunction. Whether or not the endothelial 
dysfunction caused by the imbalance between the production of NO and EDCFs can at least 
temporarily be compensated for in humans by EDHF-mediated responses [see Feletou & 
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Figure Legends:  
Figure 1. Some of the neurohumoral mediators that cause the release of 
endothelium-derived relaxing factors (EDRF) through activation of specific 
endothelial receptors (circles).  A, adrenaline (epinephrine); AA, arachidonic acid; 
Ach, acetylcholine; ADP, adenosine diphosphate; α = alpha adrenergic receptor; 
AVP, arginine vasopressin; B, kinin receptor; ET, endothelin, endothelin-receptor; 
H, histaminergic receptor; 5-HT, serotonin (5-hydroxytryptamine), serotoninergic 
receptor; M, muscarinic receptor; NA, noradrenaline (Norepinephrine); P, 
purinergic receptor; T, thrombin receptor; VEGF, vascular endothelial growth 
factorVP, vasopressin receptor. 
Figure 2. Schematic of possible mechanisms by which production of nitric 
oxide is regulated in endothelial cells.  Nitric oxide is produced through enzymatic 
conversion of L-arginine by nitric oxide synthase (endothelial or type III, eNOS).  
The transcription of this enzyme is regulated genomically by hormones and growth 
factors.  Stability of eNOS mRNA is modulated by statins and hormones.  eNOS 
enzyme activity requires calcium, calmodulin, nicotinamide adenine dinucleotide 
phosphate (NADPH), and 5, 6, 7, 8-tetra-hydrobiopterine (BH4).  Enzyme activity 
is regulated by complexing to these proteins in microdomains of the endothelial 
cell.  Association with this complex of heat shock protein 90 (HSP 90) increases 
enzyme activity. Stimulation of specific receptors on the endothelial surface (R) 
complexed with guanine nucleotide regulatory proteins, which are sensitive to 
pertussis toxin (Gi) or insensitive to pertussis toxin (Gq), activate intracellular 
pathways that modulate eNOS activity posttranslationally through heat shock 
protein 90 or AKT-phosphorylation.  Association of eNOS with caveolin-1 or 
glycosylation of the enzyme reduces activity.  A metabolite of L-arginine, 
asymmetric dimethyl arginine (ADMA) decreases production of the nitric oxide 
through competitive binding to eNOS.  Thus, this endogenous amine may be a risk 
factor for the development of cardiovascular disease.  +, indicates stimulation; -, 
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indicates inhibition; ?, indicates those pathways in which the regulation is 
unknown.  (Modified from O’Rourke et al. 2006) 
Figure 3. Multiplicity of mechanisms leading to endothelium-dependent 
hyperpolarization.    Substances such as acetylcholine (Ach), bradykinin (BK), and 
substance P (SP), through the activation of M3-muscarinic, B2-bradykinin, and 
NK1-neuroknin receptor subtypes, respectively, and agents that increase 
intracellular calcium, such as the calcium ionophore A23187, release endothelium-
derived hyperpolarizing factors. CaM, calmodulin; COX, cyclooxygenase; EET, 
epoxyeicosatrienoic acid; IP3, inositol trisphosphate; GC, guanylate cyclase; 
NAPE, N-acylphosphaticylethanolamine; Hyperol., hyperpolarization, NOS, NO 
synthase; O2·-, superoxide anions; PGI2, prostacyclin; P450, cytochrome P450 
monooxygenase; R, receptor, X, putative EDHF synthase.  SR141716 is an 
antagonist of the cannabinoid CB, receptor subtype (CB1).  Glibenclamide (Glib) is 
a selective inhibitor of ATP-sensitive potassium channels (K+ATP).  
Tetraethylammonium (TEA) and tetrabutylammonium (TBA) are nonspecific 
inhibitors of potassium channels when used at high concentrations (>5 mM), while 
at lower concentrations (1-3 mM) these drugs are selective for calcium-activated 
potassium channels (K+Ca2+).  Iberiotoxin (IBX) is a specific inhibitor of large 
conductance K+Ca2+.  Charybdotoxin (CTX) is an inhibitor of large conductance 
K+Ca2+, intermediate conductance K+Ca2+ (IK+Ca2+), and voltage-dependent 
potassium channels.  Apamin is a specific inhibitor of small conductance K+Ca2+  
(SK+Ca2+).  Barium (Ba2+), in the micromolar range, is a specific inhibitor of the 
inward rectifier potassium channel (Kir).  GAP 27 (an eleven-amino acid peptide 
possessing conserved sequence homology to a portion of the second extracellular 
loop of connexin), 18α-glycyrrhetinic acid (αGA), and heptanol are gap junction 
uncouplers.   
Figure 4. Under certain conditions, the endothelial cells, when activated by 
neurohumoral mediators, subjected to sudden stretch or exposed to the Ca2+ 
ionophore A23187, release a vasoconstrictor substance(s), termed endothelium-
derived contracting factor (EDCF(s)), which diffuses to the underlying vascular 
smooth muscle and initiates its contraction.  AA = arachidonic acid, Ach = 
acetylcholine, ADP = adenosine diphosphate, ET = endothelin, 5-HT = 5-
hydroxytryptamine, M = muscarinic receptor, P = purinoceptor, O = membrane 
receptors.   
  76
Figure 5. Postulated G-protein  mediated signal transduction processes in a 
normal, native endothelial cell.  Activation of the cell causes the release of nitric 
oxide (NO), which has important protective effects in the vascular wall.  
Abbreviations: 5-HT, serotonin receptor; B, bradykinin receptor; P, purinoceptor; 
G, coupling proteins. 
Figure 6.  Model of endothelial dysfunction in the hypercholesterolemic mouse. 
Left, In the normal mouse aortic endothelium, L-arginine (L-Arg) is transformed 
by eNOS to NO, which exerts its well-documented beneficial effects (most are not 
shown for the sake of clarity),  including inhibition of the oxidation of LDLs to 
OxLDL.  The byproduct of the reaction, L-citrulline (L-Cit), inhibits arginase II 
(AaII), which is constrained to the microtubules (MT).  Right, in the aortic 
endothelium of the ApoE-/- and the wild-type hypercholesterolemic mice, the 
accumulation of OxLDL dislocates arginase II from the microtubules and 
augments its activity.  Arginase II competes with endothelial NO synthase for the 
common substrate L-arginine, leading to uncoupling of NO synthase and the 
production of superoxide anions (O2-), which further enhance the production of 
OxLDL. The latter also facilitates dissociation of eNOS from the caveolae and 
reduces the genomic expression of the enzyme, leading to further reduction of the 
production of NO.  This model does not account for the biological effects, if any, 
of L-ornithine (L-Om) and urea produced by arginase II. It also does not account 
for endothelium-derived relaxing signals other than NO, or for the generation of 
endothelium-derived contracting substances.  CM indicates cell membrane; +, 
facilitation; -, inhibition. (Modified From Vanhoutte 2008)  
Figure 7. Two major contributors of reactive oxygen species in the vascular 
wall.  Left: L-arginine-endothelial NOS (eNOS) pathway.  Synthetic pathway of 
tetrahydrobiopterin (BH4), an essential cofactor, is also shown and some of the 
most common inhibitors of NOS, analogues of L-arginine, are indicated.  FMN, 
flavin mononucleotide; GTP, guanosine 5’-triphosphate.  Right: activation of the 
NAD(P)H oxidase (NOX).  Endothelial cells express NOX1, NOX2 (gp91phox), 
NOX4 and NOX5 isoforms, whereas vascular smooth muscle cells express the 
NOX1, NOX4 and NOX5 and in resistance arteries NOX2 isoforms.  Apocynin 
inhibits NOX by preventing translocation of cytosolic subunits and their 
association with the membrane located subunits, whereas diphenyleneiodonium 
(DPI), a flavoprotein inhibitor, is a nonspecific inhibitor of NOX. 
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(From Félétou and Vanhoutte 2006b.  By permission of the American Physiological 
Society) 
Figure 8. Effects of oxidized low-density lipoproteins (OXLDL) in a 
regenerated endothelial cell, resulting in the reduced release of nitric oxide (NO).  
Abbreviations: 5-HT, serotonin receptor; B, bradykinin receptor; P, purinoceptor; 
G, coupling proteins.   
Figure 9. Mechanisms of oxLDL-induced impairment of endothelial NO 
production.  The NO synthase (NOS) uses L-arginine to generate NO.  NO 
production could be attenuated in the presence of oxLDL by interfering with the 
supply of L-arginine to the enzyme through endogenous competitive inhibitors 
such as asymmetrical dimethyl-L-arginine (ADMA) as well as degradation of 
arginine through arginase.  NOS expression and specific activity are decreased by 
oxLDL through RhoA and PKC.  NO bioavailability is reduced by an oxLDL-
mediated activation of the NADPH oxidase, which leads to superoxide anion (O2-) 
formation.  This process facilitates the generation of peroxynitrite (ONOO-), which 
subsequently oxidizes tetrahydrobiopterin (BH4) of NOS, leading to NOS 
uncoupling.  Uncoupled NOS itself produces O2-, further promoting the process of 
BH4 oxidation.  Rho, member of the Rho protein family (either RhoA or Rac).  
(Modified from Brandes 2006) 
Figure 10: Endothelium-dependent contraction is likely to be comprised of two 
components: Generation of prostanoids and ROS. Each component depends on the 
activity of endothelial COX-1 and the stimulation of the TP receptors located on the 
smooth muscle to evoke contraction. In the SHR aorta, there is an increased 
expression of COX-1 and EP3 receptors, increased release of calcium, ROS, 
endoperoxides and other prostanoids, which facilitates the greater occurrence of 
endothelium-dependent contraction in the hypertensive rat. The necessary increase 
in intracellular calcium can be triggered by receptor-dependent agonists, such as 
acetylcholine or ADP, or mimicked with calcium increasing agents, such as the 
calcium ionophore A23187. The abnormal increase in intracellular ROS can be 
mimicked by the exogenous addition of H2O2 or the generation of extracellular ROS 
by incubation of xanthine with xanthine oxidase. AA = arachidonic acid; ACh = 
acetycholine; ADP = adenosine diphosphate; H2O2 = hydrogen peroxide; m = 
muscarinic receptors; P = purinergic receptors; PGD2 = prostaglandin D2; PGE2 = 
prostaglandin E2; PGF2α = prostaglandin F2α; PGI2 = prostacyclin; PGIS = 
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prostacyclin synthase; PLA2 = phospholipase A2; ROS = reactive oxygen species; 
TXA2 = thromboxane A2; TXAS = thromboxane synthase; X + XO = xanthine plus 
xanthine oxidase.  
Figure 11. Endothelium-dependent effects of acetylcholine in rat aorta.  Left: 
endothelium-dependent relaxations in normotensive rats.  Right: cyclooxygenase-
dependent, endothelium-dependent contractions to acetylcholine in SHR aorta.  
PGI2, prostacyclin; R, receptor; IP, PGI2 receptor; TP, TP receptor; PLA2, 
phospholipase A2; AA, arachidonic acid; COX1, cyclooxygenase 1; S-18886 
(terutroban), antagonist of TP receptors; M, muscarinic receptor, PGIS, 
prostacyclin synthase; PGH2, endoperoxides; sGC, soluble guanylyl cyclase; AC, 
adenylyl cyclase; SR, sarcoplasmic reticulum; +, activation; -, inhibition; ?, 
unknown site of formation. (From Félétou and Vanhoutte 2006b.  By pemission of 
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